Evidence map›Paper›PMID 35603853›Full record

ArticleJNCI cancer spectrum2022

Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals.

En Cheng, Dong Hoon Lee, Rulla M Tamimi, Susan E Hankinson, Walter C Willett, Edward L Giovannucci, A Heather Eliassen, Meir J Stampfer, Lorelei A Mucci, Charles S Fuchs and 1 more

Abstract read
In one paragraph

Article in JNCI cancer spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

En ChengDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0001-9523-9310
Dong Hoon LeeDepartment of Nutrition, Harvard T.H. School of Public Health, Boston, MA, USA.
Rulla M TamimiDepartment of Epidemiology, Harvard T.H. School of Public Health, Boston, MA, USA.ORCID 0000-0003-2306-8668
Susan E HankinsonDepartment of Epidemiology, Harvard T.H. School of Public Health, Boston, MA, USA.ORCID 0000-0001-9155-3767
Walter C WillettDepartment of Nutrition, Harvard T.H. School of Public Health, Boston, MA, USA.ORCID 0000-0003-1458-7597
Edward L GiovannucciDepartment of Nutrition, Harvard T.H. School of Public Health, Boston, MA, USA.
A Heather EliassenDepartment of Epidemiology, Harvard T.H. School of Public Health, Boston, MA, USA.ORCID 0000-0002-3961-6609
Meir J StampferDepartment of Nutrition, Harvard T.H. School of Public Health, Boston, MA, USA.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. School of Public Health, Boston, MA, USA.ORCID 0000-0002-2551-4927
Charles S FuchsDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.ORCID 0000-0003-1582-9842
Donna SpiegelmanYale Cancer Center, Smilow Cancer Hospital, New Haven, CT, USA.ORCID 0000-0003-4006-4650

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Life Course Cancer Epidemiology Cohort in WomenU01CA176726 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 2018 to 2025
$22.4M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Statistical Analysis and ProgrammingU19CA055075 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2010 to 2011
$8.4M
NCI NIH HHS P01 CA087969NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA176726NCI NIH HHS U19 CA055075NCI NIH HHS UM1 CA186107NIH HHS UM1 CA186107
6 · The paper itself

Abstract

backgroundFew studies investigated long-term overall survival and causes of death among men and women diagnosed with most commonly occurring cancers.

methodsWe estimated long-term (≥30-year) overall and cause-specific cumulative mortality for men diagnosed with prostate (n = 6873), lung and bronchus (n = 1290), colon and rectum (n = 1418), bladder (n = 1321), and melanoma (n = 2654) cancer in the Health Professionals Follow-up Study between 1986 and 2012 and women with breast (n = 18 280), lung and bronchus (n = 3963), colon and rectum (n = 3461), uterine corpus (n = 1641), and thyroid (n = 1103) cancer in the Nurses' Health Study between 1976 and 2012 and Nurses' Health Study II between 1989 and 2013.

resultsWe reported overall and cause-specific cumulative mortality of 30 years among men and 35 years among women. Among male cancer survivors, the 30-year cumulative cancer-specific mortality was 15.4% (95% confidence interval [CI] = 14.4% to 16.4%) for prostate, 83.5% (95% CI = 81.2% to 85.5%) for lung and bronchus, 37.0% (95% CI = 34.4% to 39.5%) for colon and rectum, 22.5% (95% CI = 20.0% to 25.0%) for urinary bladder, and 8.0% (95% CI = 6.9% to 9.1%) for melanoma. Among female cancer survivors, the 35-year cumulative cancer-specific mortality rate was 20.6% (95% CI = 19.7% to 21.6%) for breast, 83.5% (95% CI = 81.6% to 85.2%) for lung and bronchus, 39.6% (95% CI = 37.5% to 41.6%) for colon and rectum, 16.6% (95% CI = 14.7% to 18.6%) for uterine corpus, and 3.2% (95% CI = 2.1% to 4.3%) for thyroid. Except for lung cancer, most patients with common cancer were more likely to die from causes other than primary cancers. We observed 2 basic trends for cumulative cancer-specific mortality. The first is a sustained but nevertheless excess risk: Prostate or breast cancer-specific cumulative mortality continued to increase after diagnosis from 5 to 30 years or longer. The second is greatly diminished risk of index cancer-specific mortality following diagnosis 10 years or longer previously. For example, colorectal cancer-specific mortality increased by less than 4 percentage points between 10 and 30 or 35 years after diagnosis, and this finding also applied to lung, bladder, melanoma, uterine corpus, and thyroid cancer.

conclusionsExcept for lung cancer, patients diagnosed with common cancers were more likely to die from causes other than primary cancers. Patients with lung, colorectal, bladder, melanoma, uterine corpus, or thyroid cancer surviving longer than 10 years after diagnosis are unlikely to die from that disease.

Indexed as

Breast NeoplasmsLung NeoplasmsMelanomaThyroid NeoplasmsCause of DeathFemaleFollow-Up StudiesHumansIncidenceMale

Identifiers

PMID35603853
PMCPMC8973409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.